NCT02063204View on ClinicalTrials.gov

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Solid Tumours
Interventions
DRUG

selumetinib

selumetinib 50 mg (2x25mg) administered by mouth as capsules

Trial Locations (1)

Unknown

Research Site, Orlando

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY